ERAS · Erasca, Inc.

Current Thesis

• Pan-RAS molecular-glue story where the binary already fired and split. On 2026-04-27 Erasca posted best-in-class early Phase 1 dose-escalation data for ERAS-0015 (unconfirmed ORR 62% in 2L+ KRAS G12X NSCLC, 75% in post-ICI/platinum NSCLC, 64% at the 24–32 mg recommended expansion dose; 40–50% in 2L KRAS G12X pancreatic; no DLTs through 40 mg). The next session shares lost ~48% driven by two overhangs around the print, not the efficacy: a treatment-related Grade 5 pneumonitis death (66-year-old, pancreatic, 24 mg) surfaced only on the after-hours call, and a 2026-04-24 letter from Revolution Medicines asserting ERAS-0015 infringes US Patent 12,409,225 under the doctrine of equivalents, misappropriates trade secrets, and that Erasca's comparative claims were deceptive.
• The tradeable question now is recovery against a legal-plus-safety overhang rather than narrative acceleration. Shares bottomed near $10 (2026-05-07 ~$10.16), ground back to $13.18 into a 2026-06-04 BofA upgrade (Underperform→Neutral, PT $9→$16) and a same-day KeyBanc bull-flip, then gave back -9.8% to $11.97 on 2026-06-05. That is choppy mean-reversion off a gap-down with an unresolved patent dispute parked over the lead asset.
• This trades as a special-situation binary rather than a clean momentum leg. The efficacy is real and the field placement against RVMD's RMC-6236 matters, but a fresh long here underwrites an IP fight with a far-better-capitalized rival plus a new pneumonitis safety question. Probe-sized interest at most; the cleaner expression is to stand aside until the litigation path clarifies or until ERAS-4001 H2-2026 data adds a second, IP-independent leg.

Bull Case

• (data) ERAS-0015 efficacy reads best-in-class for pan-RAS: 62–75% unconfirmed NSCLC ORR and 40–50% pancreatic ORR (2026-04-27) at doses with no dose-limiting toxicities through 40 mg, low-grade AEs, no treatment-attributed discontinuations. For a pathway where RMC-6236 set the bar, FierceBiotech called the numbers a "home run."
• (analyst) Sell-side capitulation reversing: BofA Underperform→Neutral, PT $9→$16 on 2026-06-04, citing pan-RAS activity that "appears real," constructive KOL feedback, and ERAS-4001 as a second 2H-2026 opportunity; KeyBanc turned bullish the same day. Consensus 12-month PT sits ~$15.6 with a high near $18.75, all above the $11.97 close.
• (pipeline) Second IP-independent shot on goal: ERAS-4001 (pan-KRAS inhibitor) initial Phase 1 monotherapy data guided to H2 2026. A clean readout there re-rates the platform without the '225-patent cloud that hangs over ERAS-0015.
• (balance sheet) Cash runway guided into H2 2028 (per Nov-2025 disclosure), extended by the move to seek a naporafenib partner terminal dilution risk is pushed past the next two data cycles if reaffirmed on the Q2 call.
• (structure) 310.98M shares, ~6.1M average daily volume, 52-week range $1.21–$24.28: a small-cap with violent two-way gamma. Any litigation de-escalation or clean ERAS-4001 print into still-suppressed sentiment is squeeze-capable.

Bear Case

• (legal) The 2026-04-24 Revolution Medicines letter is the dominant overhang: it demands Erasca cease all US making, using, and selling of ERAS-0015 outside the Hatch-Waxman safe harbor and alleges trade-secret misappropriation plus deceptive comparative data. RevMed is far better capitalized; escalation to a filed suit or any injunctive relief on the lead asset is a -30%-plus event with no offsetting catalyst and no resolution date.
• (safety) The Grade 5 pneumonitis death deserves weight: a heavily pretreated pancreatic patient on 24 mg progressed from Grade 3 to Grade 5 pneumonitis. Erasca omitted it from the press release and disclosed it only on the call a disclosure-quality red flag and pneumonitis is a class-relevant toxicity for broad RAS-pathway inhibition. Expansion cohorts must show it was idiosyncratic.
• (litigation-2) Hagens Berman opened an investor investigation after the crash; a securities-litigation overhang compounds the patent fight and can worsen financing terms.
• (positioning) Shares already retraced ~30% off the $10 low into the upgrades, then failed -9.8% on 2026-06-05. Buying the post-upgrade bounce on an unresolved-litigation biotech is chasing strength into a known binary with no clock on it.
• (competitive) Pan-RAS is crowded and Erasca is not the leader: RVMD (RMC-6236) is ahead and is the litigant; Roche/Genentech and BMS-Mirati are better funded. ERAS-0015/4001 must differentiate on a therapeutic window unproven at scale.
• (cash) The China-rights option exercise on ERAS-0015 (worldwide rights incl. China/Hong Kong/Macau via Joyo) triggered a milestone payment that drew a Mizuho PT cut cash leaves the building while the legal cloud caps the equity.

Setup & Price Structure

• Close $11.97 on 2026-06-05 (-9.8% on the day), after-hours $11.83; market cap $3.72B on 310.98M shares; ~6.1M average daily volume.
• Gap-down anatomy: ~$19 pre-event (2026-04-27) → ~$10 on 2026-04-28 (-48%); base built near $10 (2026-05-07 $10.16); recovery to $13.18 by 2026-06-04 on the upgrades; rejected -9.8% the next session. The April gap is unfilled by a wide margin and the pre-crash $19 shelf is overhead supply.
• 52-week range $1.21–$24.28 frames the violence this name ran ~20x off its low to the 2026 peak so the current $12 handle is a deflated mid-range rather than a fresh breakout.
• Structure read: choppy reversion inside a post-crash base; calling it an uptrend is premature. A constructive entry needs either a higher-low above the ~$10 base that holds through litigation headlines, or a clean reclaim of the ~$13.20 upgrade-day high on rising volume. The -9.8% rejection on 2026-06-05 says the bounce is not yet trend.

Catalyst Calendar (next 30 days)

• No company-confirmed binary inside the window (through ~2026-07-07). The live drivers are event-gated rather than date-gated.
• Revolution Medicines IP dispute open-ended: any formal complaint filing, Erasca response or counterclaim, or settlement headline can land without notice (letter received 2026-04-24).
• ERAS-4001 (pan-KRAS) initial Phase 1 monotherapy data guided H2 2026; not date-specified, plausibly at a 2H medical meeting.
• ERAS-0015 H2 2026 initiation of monotherapy expansion and combination dose-escalation cohorts; any interim tolerability/pneumonitis follow-up is the key watch.
• Q2 2026 earnings and cash update est. early-to-mid August 2026 (outside 30 days); watch runway reaffirmation and any ATM usage.
• Continued analyst actions post-06-04 BofA/KeyBanc moves can cluster; further upgrades would confirm sentiment repair.

What Would Change Our Mind

• Bull-confirming: the Revolution Medicines dispute settled or a credible legal read that the '225 doctrine-of-equivalents claim is weak; a clean ERAS-4001 Phase 1 print in H2 2026 with no DLTs; ERAS-0015 expansion data showing the pneumonitis death was idiosyncratic with confirmed ORRs holding; daily closes reclaiming the ~$13.20 upgrade high on rising volume together these would justify upgrading from a small probe toward a genuine long thesis.
• Bear-confirming / thesis-break: RevMed files a formal infringement suit or wins any injunctive relief on ERAS-0015; a second treatment-related Grade 5 event or a pneumonitis pattern in expansion; an equity raise or ATM struck below the ~$12 area; a daily close back below the ~$10 post-crash base on volume any one of these ends the recovery read.

Correlation Notes

• Direct two-way read-through with Revolution Medicines (RVMD), the litigant and pan-RAS leader. RVMD strength on RMC-6236 both validates the mechanism and reinforces the IP threat to ERAS a positive-mechanism, negative-legal correlation. RVMD's legal stance is the single most important external tape for this name.
• Pan-RAS / KRAS basket beta: moves with the targeted-oncology cohort (RVMD, plus pan-KRAS efforts at Roche/Genentech and BMS-Mirati). Sector-wide RAS data flow shifts sentiment here.
• High-beta small-cap biotech: the 52-week $1.21–$24.28 range and ~6M ADV make ERAS an XBI amplifier it gaps multiples of the index in either direction, so XBI regime and biotech risk appetite set the backdrop.
• Idiosyncratic dominance: with an open patent fight, a fresh safety question, and a securities probe live at once, single-name headline risk swamps factor correlation macro and XBI are secondary to litigation and tolerability newsflow.